FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review
Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab
Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
FDA to Review Abuse-Deterrent Oxycodone Capsule
International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe
Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab
Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab
Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
- 1
- 2
- 3
- 4
- Next Page »